Comparison of neoadjuvant single-agent treatment and dual-HER2 blockade for breast-conserving surgery conversion in HER2-positive breast cancer: a meta-analysis
Abstract Background Neoadjuvant targeted therapy has shown that improve pathologic complete response and facilitate breast-conserving surgery, but the difference between single-agent treatment or dual-HER2 blockade to the conversion of breast-conserving surgery has not been well described. Methods V...
Saved in:
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2024-10-01
|
| Series: | BMC Cancer |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s12885-024-13052-5 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850275705984647168 |
|---|---|
| author | Manlu Cui Juan Fu Qiuyun Li |
| author_facet | Manlu Cui Juan Fu Qiuyun Li |
| author_sort | Manlu Cui |
| collection | DOAJ |
| description | Abstract Background Neoadjuvant targeted therapy has shown that improve pathologic complete response and facilitate breast-conserving surgery, but the difference between single-agent treatment or dual-HER2 blockade to the conversion of breast-conserving surgery has not been well described. Methods Via the systematic literature search of PubMed, Web of Science and Cochrane Library databases, 5 eligible studies used to perform this meta-analysis, which was carried out using RevMan version 5.4. Results A total of 1306 patients from five randomized controlled trials were included in the analysis, revealing a significant increase in the conversion rate to breast-conserving surgery with neoadjuvant targeted therapy (OR 0.30, 95% CI 0.15–0.57; p = 0.0003). The odds ratio (OR) for single-agent treatment compared to dual-HER2 blockade was 1.04 (95% CI 0.73–1.48; p = 0.82). For pathological complete response (pCR), the OR for single-HER2 blockade versus dual-HER2 blockade was 0.43 (95% CI 0.34–0.55; p = 0.01), and for clinical response, it was 0.81 (95% CI 0.59–1.10; p = 0.17). The OR for serious adverse events between single-HER2 and dual-HER2 blockade was 0.72 (95% CI 0.55–0.95; p = 0.02). The risk ratio (RR) for pCR and the shift from mastectomy to BCS was 1.16 (95% CI 0.78–1.72; p = 0.47), while for clinical response and the shift from mastectomy to BCS, it was 2.40 (95% CI 1.44–4.01; p = 0.0008). Conclusion Neoadjuvant targeted treatment obviously promote the actual implementation rate of breast-conserving surgery, nevertheless, there was no statistically significant increase in single-agent treatment versus dual-HER2 blockade. |
| format | Article |
| id | doaj-art-e19ae38d7f034fb29d395c95423ee06c |
| institution | OA Journals |
| issn | 1471-2407 |
| language | English |
| publishDate | 2024-10-01 |
| publisher | BMC |
| record_format | Article |
| series | BMC Cancer |
| spelling | doaj-art-e19ae38d7f034fb29d395c95423ee06c2025-08-20T01:50:38ZengBMCBMC Cancer1471-24072024-10-012411810.1186/s12885-024-13052-5Comparison of neoadjuvant single-agent treatment and dual-HER2 blockade for breast-conserving surgery conversion in HER2-positive breast cancer: a meta-analysisManlu Cui0Juan Fu1Qiuyun Li2Department of Breast Surgery, Guangxi Medical University Cancer HospitalDepartment of Breast Surgery, Guangxi Medical University Cancer HospitalDepartment of Breast Surgery, Guangxi Medical University Cancer HospitalAbstract Background Neoadjuvant targeted therapy has shown that improve pathologic complete response and facilitate breast-conserving surgery, but the difference between single-agent treatment or dual-HER2 blockade to the conversion of breast-conserving surgery has not been well described. Methods Via the systematic literature search of PubMed, Web of Science and Cochrane Library databases, 5 eligible studies used to perform this meta-analysis, which was carried out using RevMan version 5.4. Results A total of 1306 patients from five randomized controlled trials were included in the analysis, revealing a significant increase in the conversion rate to breast-conserving surgery with neoadjuvant targeted therapy (OR 0.30, 95% CI 0.15–0.57; p = 0.0003). The odds ratio (OR) for single-agent treatment compared to dual-HER2 blockade was 1.04 (95% CI 0.73–1.48; p = 0.82). For pathological complete response (pCR), the OR for single-HER2 blockade versus dual-HER2 blockade was 0.43 (95% CI 0.34–0.55; p = 0.01), and for clinical response, it was 0.81 (95% CI 0.59–1.10; p = 0.17). The OR for serious adverse events between single-HER2 and dual-HER2 blockade was 0.72 (95% CI 0.55–0.95; p = 0.02). The risk ratio (RR) for pCR and the shift from mastectomy to BCS was 1.16 (95% CI 0.78–1.72; p = 0.47), while for clinical response and the shift from mastectomy to BCS, it was 2.40 (95% CI 1.44–4.01; p = 0.0008). Conclusion Neoadjuvant targeted treatment obviously promote the actual implementation rate of breast-conserving surgery, nevertheless, there was no statistically significant increase in single-agent treatment versus dual-HER2 blockade.https://doi.org/10.1186/s12885-024-13052-5Breast cancerNeoadjuvantTargeted therapyDual-HER2 blockadeBreast-conserving surgeryPathologic complete response |
| spellingShingle | Manlu Cui Juan Fu Qiuyun Li Comparison of neoadjuvant single-agent treatment and dual-HER2 blockade for breast-conserving surgery conversion in HER2-positive breast cancer: a meta-analysis BMC Cancer Breast cancer Neoadjuvant Targeted therapy Dual-HER2 blockade Breast-conserving surgery Pathologic complete response |
| title | Comparison of neoadjuvant single-agent treatment and dual-HER2 blockade for breast-conserving surgery conversion in HER2-positive breast cancer: a meta-analysis |
| title_full | Comparison of neoadjuvant single-agent treatment and dual-HER2 blockade for breast-conserving surgery conversion in HER2-positive breast cancer: a meta-analysis |
| title_fullStr | Comparison of neoadjuvant single-agent treatment and dual-HER2 blockade for breast-conserving surgery conversion in HER2-positive breast cancer: a meta-analysis |
| title_full_unstemmed | Comparison of neoadjuvant single-agent treatment and dual-HER2 blockade for breast-conserving surgery conversion in HER2-positive breast cancer: a meta-analysis |
| title_short | Comparison of neoadjuvant single-agent treatment and dual-HER2 blockade for breast-conserving surgery conversion in HER2-positive breast cancer: a meta-analysis |
| title_sort | comparison of neoadjuvant single agent treatment and dual her2 blockade for breast conserving surgery conversion in her2 positive breast cancer a meta analysis |
| topic | Breast cancer Neoadjuvant Targeted therapy Dual-HER2 blockade Breast-conserving surgery Pathologic complete response |
| url | https://doi.org/10.1186/s12885-024-13052-5 |
| work_keys_str_mv | AT manlucui comparisonofneoadjuvantsingleagenttreatmentanddualher2blockadeforbreastconservingsurgeryconversioninher2positivebreastcancerametaanalysis AT juanfu comparisonofneoadjuvantsingleagenttreatmentanddualher2blockadeforbreastconservingsurgeryconversioninher2positivebreastcancerametaanalysis AT qiuyunli comparisonofneoadjuvantsingleagenttreatmentanddualher2blockadeforbreastconservingsurgeryconversioninher2positivebreastcancerametaanalysis |